反応式
[CH2:1]1[CH:3]([CH2:4][N:5]2[C@@H:15]3[CH2:16][C:17]4[CH:22]=[CH:21][C:20]([OH:23])=[C:19]5[O:24][CH:9]6[C:10]([CH2:12][CH2:13][C@:14]3([OH:25])[C@:8]6([C:18]=45)[CH2:7][CH2:6]2)=[O:11])[CH2:2]1>C(O)C1C=CC=CC=1>[CH2:2]1[CH:3]([CH2:4][N:5]2[CH:15]3[CH2:16][C:17]4[CH:22]=[CH:21][C:20]([OH:23])=[C:19]5[O:24][CH:9]6[C:10]([CH2:12][CH2:13][C:14]3([OH:25])[C:8]6([C:18]=45)[CH2:7][CH2:6]2)=[O:11])[CH2:1]1.[CH2:19]([OH:24])[C:18]1[CH:8]=[CH:14][CH:15]=[CH:16][CH:17]=1参加物
4
実験手順
A 1 kg batch of naltrexone microspheres were prepared as follows. Polymer solution was formed by dissolving 75:25 DL PLGA (poly(lactide)-co-glycolide) in ethyl acetate (EtAc) to form a solution of 16.7% polymer and 83.3% EtAc. A naltrexone solution was formed by dissolving naltrexone base in benzyl alcohol (BA) to form a solution of 30% naltrexone base anhydrous and 70% BA. The polymer solution and the naltrexone solution were mixed together to form a drug/polymer solution that was the “organic” or “oil” phase of the emulsion.
出典と根拠
- ORDレコード
- ord-17e634018c2144318a8ecbaf518c7585
- 出典データセット
- uspto-grants-2015_12
- 特許番号
- US09221830B2
関連ノート
読み込み中…